Why Hedge Funds Are Stacking Into These 2 High Yielding Stocks
As we move into the second half of the year, many investors will need to reposition themselves to better spread their investments to mitigate risk. Some investors prefer to take positions in stocks purchased by hedge funds because large institutional ownership can create greater demand for stocks.
Whether you follow your favorite hedge fund manager or activist investor, it can be interesting to find out the main owners of a stock. For example, Wells Fargo's top two hedge fund shareholders are Eagle Capital Management and Pzena Investment Manager, worth $709 million and $666 million, respectively, per Hedge Follow.
While Merck & Co's two largest hedge fund shareholders are Barrow Hanley Mewhinney Strauss Holdings and Renaissance Technologies, with a total value of $996 million and $617 million, respectively. These two dividend-paying stocks are hedge fund favorites as we head into the second half of the year.
Wells Fargo & Co. WFC offers a dividend yield of 2.76% or $1.20 per share per year, making quarterly payments, with a decent track record of increasing its dividends for two years. Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets in 2021.
In the second quarter of 2022, Wells Fargo recorded period-end loans of $944 billion, up 11% from the second quarter of the previous year and 4% compared to the first quarter of 2022.< /p>
"Going forward, our results should continue to benefit from rising interest rates, with growth in net interest income more than offsetting any further near-term pressure on non-interest income. We expect credit losses to rise from these incredibly low levels, but we have not yet seen any significant deterioration in our consumer or commercial portfolios,” said Managing Director Charlie Scharf.
>Go to: 3 Benefits on What an 8.3% Inflation Rate Means for the Fed: "A Strategic Mistake of Epic Proportions "< /p>
Merck & Co. Inc MRK offers a dividend yield of 3.12% or $2.76 per share per year, using quarterly payouts, with a strong track record of increasing its dividends for 11 consecutive years. Merck & Co. manufactures pharmaceuticals to treat several conditions in a number of therapeutic areas, including cardiometabolic diseases, cancer, and infections.
In the second quarter of 2022, global sales were $14.6 billion, an increase of 28% compared to the second quarter of 2021.
“Our strategy is working and our future is bright. I am confident that we are well positioned to achieve our short and long-term goals, anchored in our commitment to bringing innovative medicines and vaccines to patients and delivering value to all of our stakeholders, including shareholders." , Robert M. Davis, commented CEO and President.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
As we move into the second half of the year, many investors will need to reposition themselves to better spread their investments to mitigate risk. Some investors prefer to take positions in stocks purchased by hedge funds because large institutional ownership can create greater demand for stocks.
Whether you follow your favorite hedge fund manager or activist investor, it can be interesting to find out the main owners of a stock. For example, Wells Fargo's top two hedge fund shareholders are Eagle Capital Management and Pzena Investment Manager, worth $709 million and $666 million, respectively, per Hedge Follow.
While Merck & Co's two largest hedge fund shareholders are Barrow Hanley Mewhinney Strauss Holdings and Renaissance Technologies, with a total value of $996 million and $617 million, respectively. These two dividend-paying stocks are hedge fund favorites as we head into the second half of the year.
Wells Fargo & Co. WFC offers a dividend yield of 2.76% or $1.20 per share per year, making quarterly payments, with a decent track record of increasing its dividends for two years. Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets in 2021.
In the second quarter of 2022, Wells Fargo recorded period-end loans of $944 billion, up 11% from the second quarter of the previous year and 4% compared to the first quarter of 2022.< /p>
"Going forward, our results should continue to benefit from rising interest rates, with growth in net interest income more than offsetting any further near-term pressure on non-interest income. We expect credit losses to rise from these incredibly low levels, but we have not yet seen any significant deterioration in our consumer or commercial portfolios,” said Managing Director Charlie Scharf.
>Go to: 3 Benefits on What an 8.3% Inflation Rate Means for the Fed: "A Strategic Mistake of Epic Proportions "< /p>
Merck & Co. Inc MRK offers a dividend yield of 3.12% or $2.76 per share per year, using quarterly payouts, with a strong track record of increasing its dividends for 11 consecutive years. Merck & Co. manufactures pharmaceuticals to treat several conditions in a number of therapeutic areas, including cardiometabolic diseases, cancer, and infections.
In the second quarter of 2022, global sales were $14.6 billion, an increase of 28% compared to the second quarter of 2021.
“Our strategy is working and our future is bright. I am confident that we are well positioned to achieve our short and long-term goals, anchored in our commitment to bringing innovative medicines and vaccines to patients and delivering value to all of our stakeholders, including shareholders." , Robert M. Davis, commented CEO and President.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
What's Your Reaction?
